Introduction

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: August 15, 2017; Expiration date: August 15, 2018

Learning Objectives

Upon completion of this activity, participants will be able to:

•     Identify the life cycle of Mansonella perstans.

•     Distinguish the most common country of origin among patients infected with Mansonella perstans in the current study.

•     Assess common symptoms of infection with Mansonella perstans.

•     Identify first-line treatment for Mansonella perstans in the current study.

CME Editor

Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor, UC Irvine Department of Family Medicine; Associate Dean for Diversity and Inclusion, UC Irvine School of Medicine, Irvine, California, USA. Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.

Authors

Disclosures: Federico Gobbi, PhD, MD, DTM&H; Anna Beltrame, MD, PhD; Dora Buonfrate, MD, DTM&H; Silvia Staffolani, MD; Monica Degani; Maria Gobbo; Andrea Angheben, MD; Stefania Marocco, MD; and Zeno Bisoffi, MD, PhD, DTM&H, have disclosed no relevant financial relationships.

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title:
Imported Infections with Mansonella perstans Nematodes, Italy

CME Questions

1.   You are seeing a 30-year-old man who recently emigrated from sub-Saharan Africa. His sister, who emigrated from their home country years ago, brings him in "to get checked out for any illnesses or parasites." You consider whether the patient might have infection with Mansonella perstans. Which one of the following statements regarding the life cycle of M. perstans is most accurate?

A.  It is transmitted to humans via mosquitoes

B.  Macrofilariae live in serous body cavities

C.  Macrofilariae are the final infection stage of M. perstans

D.  Microfilariae are released into the bloodstream approximately 1 month after the initial infection

2.   Which one of the following countries was associated with the highest number of infections with M. perstans in the current study?

A.  Tanzania

B.  Democratic Republic of the Congo

C.  Mozambique

D.  Sudan

3.   You perform a review of systems for infection. Which one of the following symptoms was most common among individuals with M. perstans in the current study?

A.  Itching

B.  Edema

C.  Arthralgia

D.  Abdominal pain

4.   The patient's symptoms and serologic testing suggest infection with M. perstans. According to the results of the current study, what has been first-line treatment for M. perstans since 2009?

A.  Levamisole, followed by mebendazole

B.  Mebendazole alone

C.  Albendazole, followed by ivermectin

D.  Mebendazole, followed by doxycycline

Activity Evaluation